| 货号 | 0916/50 |
| 别名 | (S)-(-)-3-Bromo-N-[(1-ethyl-2-pyrro |
| 供应商 | Tocris |
| 生物活性 | Dopamine D2 receptor antagonist showing selectivity over D3 and D4 receptors (Ki values are ~ 300, ~ 1600, and ~ 2800 nM for D2, D3 and D4 receptors respectively). Exhibits antipsychotic activity in vivo with no extrapyramidal side effects. 50-fold more potent than sulpiride in antagonising the effects of apomorphine in the rat. |
| 运输条件 | Blue Ice |
| 存放说明 | Ambient |
| 计算分子量 | 407.73 |
| 分子式 | C16H23BrN2O3.HCl |
| 可溶性/溶解性 | Soluble to 100 mM in water |
| CAS号 | 73220-03-8 |
| 参考文献 | Ahleniuset al(1997)In vivo effects of remoxipride and aromatic ring metabolites in the rat. J.Pharmacol.Exp.Ther. 283 1356. PMID: 9400011. Seeman and Van Tol (1994) Dopamine receptor pharmacology. TiPS 15 264. PMID: 7940991. Mohellet al (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur.J.Pharmacol. 238 121. PMID: 8405075. Sedvall (1990) Development of a new antipsychotic remoxipride. Acta Psychiatr.Scand.Suppl. 358 1. PMID: 1978466. |